SAB Biotherapeutics
SABS
SABS
38 hedge funds and large institutions have $3.28M invested in SAB Biotherapeutics in 2023 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 5 closing their positions.
New
Increased
Maintained
Reduced
Closed
more capital invested
Capital invested by funds: $ → $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more ownership
Funds ownership: →
less funds holding
Funds holding: →
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
Holders
38
Holding in Top 10
–
Calls
–
Puts
–
Top Buyers
| 1 | +$217K | |
| 2 | +$45K | |
| 3 | +$43K | |
| 4 |
IFAM
Institutional & Family Asset Management
Fort Collins,
Colorado
|
+$35.1K |
| 5 |
Prudential Financial
Newark,
New Jersey
|
+$30K |
Top Sellers
| 1 | -$78.2K | |
| 2 | -$59.2K | |
| 3 | -$47.6K | |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$12.5K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$2.94K |